Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Champions Oncology's Enterprise Value is $67.57 Mil.
Champions Oncology's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-8.80 Mil. Therefore, Champions Oncology's EV-to-EBIT ratio for today is -7.68.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Champions Oncology's Enterprise Value is $67.57 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-6.81 Mil. Therefore, Champions Oncology's EV-to-EBITDA ratio for today is -9.93.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Champions Oncology's Enterprise Value is $67.57 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $49.22 Mil. Therefore, Champions Oncology's EV-to-Revenue ratio for today is 1.37.
Champions Oncology Enterprise Value Historical Data
The historical data trend for Champions Oncology's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Champions Oncology's Enterprise Value
For the Biotechnology subindustry, Champions Oncology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Enterprise Value falls into.
Champions Oncology Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Champions Oncology's Enterprise Value for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (NAS:CSBR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Champions Oncology's current Enterprise Value is $67.57 Mil.
Champions Oncology's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.80 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Champions Oncology's current Enterprise Value is $67.57 Mil.
Champions Oncology's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.81 Mil.
Champions Oncology's current Enterprise Value is $67.57 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $49.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Enterprise Value Related Terms
Thank you for viewing the detailed overview of Champions Oncology's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Champions Oncology (Champions Oncology) Business Description
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSBR has been successfully added to your 